Metamark Genetics Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
24
- Latest Deal Type
-
2ndary - Private
Metamark Genetics General Information
Description
Developer of advanced proteomics platform designed to address the complete diagnostic and therapeutic journey of a prostate cancer patient. The company's technology platform has distinct advantages, including sensitivity and accuracy, the ability to predict progression risk at an early-stage disease, and has the ability to overcome challenges of tumor heterogeneity, fully automated and digitalized tissue analyses independent of subjective interpretations, enabling patients and their physicians to make informed treatment decisions that lead to a quality of life and low cost of care.
Contact Information
Website
www.metamarkgenetics.comCorporate Office
- 283 Bear Hill Road
- Waltham, MA 02451
- United States
Corporate Office
- 283 Bear Hill Road
- Waltham, MA 02451
- United States
Metamark Genetics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 01-Aug-2021 | 0000 | Completed | Profitable | ||
| 4. Later Stage VC (Series B2) | 14-Nov-2012 | 00.00 | 0000 | 00000 | Completed | Profitable |
| 3. Early Stage VC (Series B) | 02-Jul-2010 | 000.00 | 000.00 | 0000 | Completed | Profitable |
| 2. Early Stage VC (Series A1) | 06-May-2009 | $2.65M | $12.7M | 0000 | Completed | Profitable |
| 1. Early Stage VC (Series A) | $10M | $10M | 0000 | Completed | Startup |
Metamark Genetics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B2 | 0,000,000 | 00.000000 | 00.0 | 00.0 | 00.0 | 0.000 | ||
| Series B1 | 00,000,000 | 00.000000 | 00.0 | 00.0 | 00.0 | 00.000 | ||
| Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00.000 | ||
| Series A1 | 7,895,000 | $0.001000 | $1.33 | $1.33 | $0.99 | 13.3% | ||
| Series A | 10,500,000 | $0.001000 | $1 | $1 | $0.79 | 16.54% |
Metamark Genetics Comparisons
Industry
Financing
Details
000000
000000
Metamark Genetics Competitors (20)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Strata Oncology | Venture Capital-Backed | Ann Arbor, MI | 00 | 00000 | 00000000000 | 00000 |
| CirculoGene | Venture Capital-Backed | Birmingham, AL | 00 | 000.00 | 000000000 | 000.00 |
| Novigenix | Venture Capital-Backed | Epalinges, Switzerland | 00 | 0000 | 00000000000 | 0000 |
| Biocept | Formerly VC-backed | San Diego, CA | 00 | 00000 | 000000000000 | 00000 |
| Pathway | Venture Capital-Backed | Montreal, Canada | 00 | 00.00 | 0000000000 0 | 00.00 |
Metamark Genetics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Metamark Genetics Patents
Metamark Genetics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20160266126-A1 | Compositions and methods for cancer prognosis | Inactive | 15-Mar-2013 | 000000000000 | |
| US-20200150123-A1 | Tumor markers fus, smad4, derl1, ybx1, ps6, pdss2, cul2, and hspa9 for analyzing prostate tumor samples | Inactive | 15-Mar-2013 | 000000000000 | |
| CA-2904441-A1 | Compositions and methods for cancer prognosis | Inactive | 15-Mar-2013 | 000000000000 | |
| EP-2971110-A2 | Compositions and methods for cancer prognosis | Inactive | 15-Mar-2013 | G01N33/57434 | 0 |
Metamark Genetics Executive Team (18)
| Name | Title | Board Seat |
|---|---|---|
| Kenneth Weg | Co-Founder, Chairman, President & Chief Executive Officer | |
| Peter Maimonis Ph.D | Chief Scientific Officer & Senior Vice President, Research & Development | |
| Jerome Richie MD | Chief Medical Officer | |
| Ronald DePinho MD | Co-Founder |
Metamark Genetics Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Mansoor Mirza MD | Self | Board Member | 000 0000 |
| Norman Selby | Self | Board Member | 000 0000 |
Metamark Genetics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Metamark Genetics Acquisitions (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| HealthTronics Laboratory Solutions | 12-Aug-2013 | 0000000000 | Laboratory Services (Healthcare) | 00000 000 |
Metamark Genetics FAQs
-
When was Metamark Genetics founded?
Metamark Genetics was founded in 2007.
-
Who is the founder of Metamark Genetics?
Kenneth Weg, David Rimm Ph.D, Ronald DePinho MD, and Lynda Chin MD are the founders of Metamark Genetics.
-
Who is the CEO of Metamark Genetics?
Kenneth Weg is the CEO of Metamark Genetics.
-
Where is Metamark Genetics headquartered?
Metamark Genetics is headquartered in Waltham, MA.
-
What is the size of Metamark Genetics?
Metamark Genetics has 24 total employees.
-
What industry is Metamark Genetics in?
Metamark Genetics’s primary industry is Laboratory Services (Healthcare).
-
Is Metamark Genetics a private or public company?
Metamark Genetics is a Private company.
-
What is Metamark Genetics’s current revenue?
The current revenue for Metamark Genetics is 000000.
-
How much funding has Metamark Genetics raised over time?
Metamark Genetics has raised $48M.
-
Who are Metamark Genetics’s competitors?
Strata Oncology, CirculoGene, Novigenix, Biocept, and Pathway are some of the 20 competitors of Metamark Genetics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
